Isuventatug

伊苏妥塔单抗

Report date: 2025/11/10 17:51:52
First In Class

Base Information

Drug NameIsuventatug
Drug Alias NameCLN-619
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-MICA +[4] 
TargetsMHC class I polypeptide-related sequence AMHC class I polypeptide-related sequence B
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCullinan MICA Corp
China Registration ClassN/A

Develop Information

Active CompaniesCullinan Therapeutics Inc
Inactive CompaniesCullinan MICA Corp
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A